Central serous chorioretinopathy: A pathogenetic model

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 239-243

  Caccavale, Antonio ^a   Romanazzi, Filippo ^a   Imparato, Manuela ^a   Negri, Angelo ^b   Morano, Anna ^c   Ferentini, Fabio ^b  

^a Neuropthalmology and Ocular Immunology Service   (Italy)

^b Department of Ophthalmology   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Aspirin; Cscr; Glucocorticoid; Macula; Pai 1; Pathogenesis

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; KETOCONAZOLE; MIFEPRISTONE; PLASMINOGEN ACTIVATOR; VERTEPORFIN;

ARTICLE; BLEEDING; CENTRAL SEROUS RETINOPATHY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LASER COAGULATION; LOW DRUG DOSE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PROTEIN FUNCTION; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION;

EID: 79952850215     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S17182     Document Type: Article

References (60)

1. Von Graefe A. Ueber centrale recidivirende Retinitis. Albrecht von Graefe's Arch Klin Ophthalmol. 1866;12:211.
2. Horniker E. Ueber eine Form von zentraler Retinitis auf angioneurotischer Grundlage [Retinitis centralis angioneurotica]. Albrecht von Graefe's Arch Klin Ophthalmol. 1930;123:286.
3. Gass JDM. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967;63:587.
4. Wang M, Munch CI, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126-145.
5. Klein ML, van Buskirk ME, Friedman E, Gragoudas E, Chandra S. Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol. 1974;91:247-250.
6. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996;114:689-692.
7. Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand. 2001;79: 417-421.
8. Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2002;133:787-793.
9. Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol. 1986;9: 37-41.
10. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14:231-242.
11. Iida T, Hagimura N, Otani T, Ikeda F, Muraoka K. Choroidal vascular lesions in serous retinal detachment viewed with indocyanine green angiography. Nippon Ganka Gakkai Zasshi. 1996;100:817-824.
12. Giovannini A, Scassellati-Sforzolini B, D'Altobrando E, Mariotti C, Rutili T, Tittarelli R. Choroidal findings in the course of idiopathic serous pigment detachment detected by indocyanine green videoangiography. Retina. 1997;17:286-293.
13. Menchini U, Virgili G, Lanzetta P, Ferrari E. Indocyanine green angiography in central serous chorioretinopathy. Int Ophthalmol. 1997; 21:57-69.
14. Yannuzzi LA. Type a behavior and central serous chorioretinopathy. Retina. 1987;7:111-131.
15. Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI. Central serous chorioretinopathy in endogenous chorioretinopathy. Arch Ophthalmol. 1993;111:1229-1233.
16. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003; 110:698-703.
17. Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic- parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophth Vis Sci. 2006;47: 3474-3478.
18. Song E, Wakakura M, Ishikawa S. Central serous chorioretinopathy induced by corticosteroids. Nippon Ganka Gakkai Zasshi. 1997; 101:257-264.
19. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47:431-448.
20. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case control study. Ophthalmology. 2004;111:244-249.
21. Yamada R, Yamada S, Ishii A, Tane S. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi. 1993;97:955-960.
22. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina. 1999;19:508-512.
23. Kitaya N, Nagaoka T, Hikichi T. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol. 2003; 87:709-712.
24. Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol. 2004;2:1-12.
25. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab. 1986;62:275-279.
26. Whitworth JA, Connell JM, Lever AF, Fraser R. Pressor responsiveness in steroid-induced hypertension in man. Clin Exp Pharmacol Physiol. 1986;13:353-358.
27. Walker BR, Williams BC. Corticosteroids and vascular tone: mapping the messenger maze. Clin Sci. 1992;82:597-605.
28. Gaillard RC, Poffet D, Riondel AM, Saurat JH. RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab. 1985;61:1009-1011.
29. Jones JP Jr. Intravascular coagulation and osteonecrosis. Clin Orthop. 1992;277:41-53.
30. Nyklícek I, Bosch JA, Amerongen AV. A generalized physiological hyperreactivity to acute stressors in hypertensives. Biol Psychol. 2005;70:44-51.
31. Williamson TH, Harris A. Ocular blood flow measurement. Br J Ophthalmol. 1994;78:939-945.
32. Flower RW, Fryczkowski AW, Scott McLeod D. Variability in choriocapillaris blood flow distribution. Inv Ophthalmol Vis Sci. 1995; 36:1247-1258.
33. Flower RW, von Kerczek C, Zhu L, Ernest A, Eggleton C, Topoleski LDT. Theoretical investigation of the role of choriocapillaris blood flow in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration. Am J Ophthalmol. 2001;132:85-93.
34. Hayreh SS. Segmental nature of the choroidal vasculature. Br J Ophthalmol. 1975;59:631-48.
35. Haigh RM, Jones CT. Effect of glucocorticoids on alpha 1-adrenergic receptor receptor binding in rat vascular smooth muscle. J Mol Endocrinol. 1990;5:42-48.
36. Matsuura M, Ando F, Matsuura M. Stellate ganglion block therapy in central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi. 1981;85:1485-1491.
37. Heinrich MR. Central serous retinopathy and alpha-blockaders. Bull Soc Ophtalmol Fr. 1994;74:681-683.
38. Fabianová J, Porubská M, Cepilová Z. Central serous chorioretinopathy- treatment with beta blockers. Cesk Slov Oftalmol. 1998;54:401-404.
39. Avci R, Deutman AF. Treatment of central serous choroidopathy with the beta receptor blocker metoprolol. Klin Monbl Augenheilkd. 1993;202:199-205.
40. Chrapek O, Spacková K, Rehák J. Treatment of central serous chorioretinopathy with beta blockers. Cesk Slov Oftalmol. 2002;58:382-386.
41. Browning DJ. Nadolol in the treatment of central serous chorioretinopathy. Am J Ophthalmol. 1993;116:770-771.
42. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109:1723-1725.
43. Dallinger S, Bobr B, Findl O, Eichler HG, Schmetterer L. Effects of acetazolamide on choroidal blood flow. Stroke. 1998;29:997-1001.
44. Kiss B, Dallinger S, Findl O, Rainer G, Eichler HG, Schmetterer L. Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide. Am J Physiol. 1999;276:R1661-R1667.
45. Fuchsjäger-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89: 1293-1297.
46. Nielsen JS, Weinreg RN, YannuzziL, Jampol LM. Mifepristone treatment of chronic central serous chorioretinopathy. Retina. 2007; 27:119-122.
47. Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007;27:943-946.
48. Golshahi A, Klingmüller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol. 2010;88:576-581.
49. Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol. 1999; 127:477-478.
50. Caccavale A, Imparato M, Romanazzi F, Negri A, Porta A, Ferentini F. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses. 2009;73:435-437.
51. Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2001;4:899-903.
52. Nye EJ, Hockings GI, Grice JE, et al. Aspirin inhibits vasopressininduced hypothalamic-pituitary-adrenal activity in normal humans. J Clin Endocrinol Metab. 1997;82:812-817.
53. Di Luigi L, Guidetti L, Romanelli F, Baldari C, Conte D. Acetylsalicylic acid inhibits the pituitary response to exercise-related stress in humans. Med Sci Sports Exerc. 2001;33:2029-2035.
54. Roth GJ, Calverley DC. Aspirin, platelets and thrombosis: theory and practice. Blood. 1994;83:885-898.
55. Collaborative overview of randomized antiplatelet therapy-1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106.
56. Sivaprasad S, Elagouz m, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical application. Surv Ophthalmol. 2010;55:516-530.
57. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol. 2010;149:441-446.
58. Niegel MF, Schrage NF, Christmann S, Degenring RF. Intravitreal bevacizumab for chronic central serous chorioretinopathy. Ophthalmologe. 2008;105:943-945.
59. Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina. 2010;30:1465-1471.
60. Wolfensberger TJ, Gregor ZJ. Macular edema - rationale for therapy. Dev Ophthalmol. 2010;47:49-58.